Israel’s largest pharmaceutical company, Teva, has taken a hit recently, with the company’s shares losing half of their value. CEO Erez Vigodman still has the support of the company board despite the tough times, and analysts believe that Vigodman can turn the ship around. Some analysts believe that Teva’s acquisition of Actavis, Allergan’s generics unit, was too costly. Several weeks ago, Sigurdur Olafsson, the President of Teva’s generic division, who was responsible for assimilating Actavis, unexpectedly resigned. Teva’s failed acquisition of Mexican firm Rimsa also shook the confidence of investors.